To include your compound in the COVID-19 Resource Center, submit it here.

Expanded deal with Kyowa could give MEI cash through drug approval

Building on a 2018 deal in Japan, MEI Pharma granted Kyowa Kirin ex-U.S. rights to its PI3Kδ inhibitor ME-401 in an expanded partnership that could shore up the San Diego-based biotech’s balance sheet through a regulatory approval.

MEI Pharma Inc. (NASDAQ:MEIP) will receive $100 million up front in Tuesday’s deal and is eligible for $582.5 million

Read the full 556 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE